Zacks Investment Research2 Σεπ 2026, 3:30 μ.μ.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals beat Q2 2026 earnings estimates with adjusted EPS of $1.15 (vs. $0.97 consensus) and revenues of $343 million (vs. $308 million consensus), driven by strong Sublocade performance. The company raised its full-year 2026 guidance and improved profitability through cost management. Despite these positive results, shares have declined 5.3% since the earnings report, underperforming the S&P 500. The stock holds a Zacks Rank #2 (Buy) with upward estimate revisions.
